Khoury, Katia
Lynce, Filipa
Barac, Ana
Geng, Xue
Dang, Chau
Yu, Anthony F.
Smith, Karen L.
Gallagher, Christopher
Pohlmann, Paula R.
Nunes, Raquel
Herbolsheimer, Pia
Warren, Robert
Srichai, Monvadi B.
Hofmeyer, Mark
Asch, Federico
Tan, Ming
Isaacs, Claudine
Swain, Sandra M. http://orcid.org/0000-0002-1320-3830
Funding for this research was provided by:
Genentech (ML28685)
National Cancer Institute (P30CA051008)
Conquer Cancer Foundation
Georgetown-Howard Universities Center for Clinical and Translational Science
Article History
Received: 23 September 2020
Accepted: 7 December 2020
First Online: 5 January 2021
Compliance with ethical standards
:
: K. Khoury, X. Geng, R. Warren, M. Srichai, M. Hofmeyer, and F. Asch, report no competing interests. F. Lynce reports consulting/advisory role from Bristol-Myers Squibb, Jounce Therapeutics (unpaid), AstraZeneca and Pfizer/EMD Serono, association with the speakers’ bureau for ASCO, travel, accommodations and expenses from Bristol-Myers Squibb and Genentech, has received research funding from Pfizer, Bristol-Myers Squibb and Inivata, and institution-associated research funding from Calithera Biosciences, Immunomedics, Chugai Pharma USA, Regeneron, Inivata, and Tesaro. A. Barac reports consulting/advisory role from Takeda Science Foundation. C. Dang reports consulting/advisory role and travel, accommodations and expenses and has received honoraria from Genentech/Roche, Puma Biotechnology, Lilly, and has received research institution-associated funding from Genentech/Roche and Puma Biotechnology. A. Yu reports consulting/advisory role from AstraZeneca and Genentech for himself and an immediate family member, and research funding from AstraZeneca received for an immediate family member. K. Smith reports stock and ownership interest in Abbvie and Abbott laboratories, and has received institution-associated funding from Pfizer. C. Gallagher reports consulting/advisory role from Seattle Genetics, and association with the speakers’ bureau for Daiichi-Sankyo. P. Pohlmann reports consulting/advisory role from Personalized Cancer Therapy, OncoPlex Diagnostics, Immunonet BioSciences, Pfizer, HERON, Puma Biotechnology, Sirtex Medical, Caris Life Sciences, SeaGen and Juniper, association with the speakers’ bureau for Genentech/Roche, patents: United States Patent no. 8,486,413, United States Patent no. 8,501,417, United States Patent no. 9,023,362, United States Patent no. 9,745,377, stock/ownership and leadership in Immunonet BioSciences, received honoraria from ASCO and Dava Oncology, and institution-associated research funding from Genentech/Roche, Fabre-Kramer, Advanced Cancer Therapeutics, Caris Centers of Excellence, Pfizer, Pieris Pharmaceuticals, BOLT, SeaGen, Byondis, and Cascadian Therapeutics. R. Nunes reports consulting/advisory role from Agendia (unpaid), and has received research funding from bioTheranostics. P. Herbolsheimer is an employee of AstraZeneca, and reports travel, accommodations and expenses and stock/ownership from AstraZeneca. M. Tan reports consulting/advisory role from American Gene Technologies, has received honoraria from AstraZeneca, Incyte, Otsuka, and Sanofi Pasteur, travel and accommodations from Otsuka, and research funding from Genentech. C. Isaacs reports consulting/advisory role from Pfizer, Genentech/Roche, Novartis, AstraZeneca, Puma Biotechnology, Context Therapeutics, and Seattle Genetics, association with the speakers’ bureau for Genentech, Pfizer, and AstraZeneca, received honoraria from Genentech/Roche, AstraZeneca, and Pfizer, and institution-associated research funding from Novartis, Pfizer, Genentech, and Tesaro. S. Swain reports consulting/advisory or non promotional speaking role from Exact Sciences (Genomic Health), Genentech/Roche, Daiichi Sankyo, Athenex, Natura, and Silverback Therapeutics, IDMC from AstraZeneca, support for third party writing assistance from Genentech/Roche, and institution-associated research funding from Genentech and Kailos Genetics. The COI’s described above include competing interests of greater than 1 year.